ClinicalTrials.Veeva

Menu

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Kissei logo

Kissei

Status and phase

Completed
Phase 3

Conditions

Endometriosis

Treatments

Drug: 200 mg linzagolix tablet
Drug: Placebo capsule to match Add-back capsule
Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Drug: 75 mg linzagolix tablet
Drug: Placebo tablet to match 200 mg linzagolix tablet
Drug: Placebo tablet to match 75 mg linzagolix tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT03992846
18-OBE2109-003

Details and patient eligibility

About

The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).

Full description

This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the management of moderate to severe EAP in 450 women.

Eligible subjects who have completed the 6-month treatment period may enter a separate extension study for 6 additional months of active treatment (no placebo control). Subjects who do not continue in the extension study will enter a 6 month treatment-free follow-up phase.

Enrollment

486 patients

Sex

Female

Ages

18 to 49 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The subject must have:

  • Her most recent surgical and - if available - histological diagnosis of pelvic endometriosis up to 10 years before screening.
  • Moderate to severe endometriosis-associated pain during the screening period.
  • Regular menstrual cycles.
  • BMI ≥ 18 kg/m2 at the screening visit. -

Exclusion criteria

The subject will be excluded if she:

  • Is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.
  • Is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of entry into the screening period.
  • Has had a surgical history of any major abdominal surgery within 6 months or any interventional surgery for endometriosis performed within a period of 2 months before screening.
  • Did not respond to prior treatment with GnRH agonists or GnRH antagonists for endometriosis.
  • Has a history of, or known, osteoporosis or other metabolic bone disease.
  • Has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic or other chronic therapy which would interfere with the assessment of endometriosis-associated pain.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

486 participants in 3 patient groups, including a placebo group

Linzagolix 75 mg
Experimental group
Treatment:
Drug: Placebo tablet to match 200 mg linzagolix tablet
Drug: 75 mg linzagolix tablet
Drug: Placebo capsule to match Add-back capsule
Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)
Experimental group
Treatment:
Drug: Placebo tablet to match 75 mg linzagolix tablet
Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Drug: 200 mg linzagolix tablet
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo tablet to match 75 mg linzagolix tablet
Drug: Placebo tablet to match 200 mg linzagolix tablet
Drug: Placebo capsule to match Add-back capsule

Trial documents
2

Trial contacts and locations

71

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems